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Objective: The purpose of this study was to investigate pregnancy outcomes in women with epilepsy using lamotrigine (LTG).
Methods: We retrospectively reviewed the medical records of all patients who had been diagnosed as epilepsy and gave live singleton births 
in Yonsei University Health System, Seoul, Korea, between February 1996 and December 2007. Nine patients who were not taking 
antiepileptic drugs (AEDs) were excluded from this study. We subdivided the enrolled patients into 2 groups; patients exposed to LTG 
and others exposed to other AEDs. Congenital malformation, spontaneous abortion, small for gestational age, termination of pregnancy, 
intrauterine fetal death, preterm delivery, and adverse maternal outcomes were documented to evaluate the pregnancy outcomes. The 
statistical significance was defined as P<0.05.
Results: 129 cases were found in all medical records. The overall risk of congenital malformations in the AED group was 6.2% (n=8), which 
included 4 cases to carbamazepine (CBZ) monotherapy, 1 to valproate (VPA) monotherapy, and 3 to VPA+CBZ polytherapy. Congenital 
malformations were significantly increased in the non- LTG groups than in the LTG group (8.7% vs. 0%, P=0.047), especially in non-LTG 
polytherapy group (20.0% vs. 0%, P=0.049). The rates of spontaneous abortion, small for gestational age, termination of pregnancy, 
intrauterine fetal death, preterm delivery, and adverse maternal outcomes were no significant differences between the two groups. 
Conclusion: This study demonstrates that administration of LTG in pregnant women with epilepsy could be more effective in decreasing 
teratogenicity than administration of other AEDs in polytherapy. 
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Introduction
Epilepsy affects 0.5~1% of the general population. 
One-third of women of reproductive age, approximately 
0.3~0.6% of pregnant women, are exposed to anti-
epileptic drugs (AEDs).1 The majority of these pregnan-
cies are uncomplicated, but it is known that there are 
increased adverse outcomes such as seizure (33%), vag-
inal bleeding (10%), fetal deformity (4~6%), pre-
eclampsia, and extraction and cesarean delivery com-
pared to women who do not take AEDs.2 Risk of sponta-
neous abortion, intrauterine fetal death (IUFD), intra-
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uterine growth restriction (IUGR), and perinatal fetal 
death could increase in women with epilepsy compared 
to general population.3
The goal of epilepsy treatment during pregnancy is 
seizure control using AEDs, despite the fact that tradi-
tional AEDs are known teratogens. There have been in-
sufficient studies on the relationship between obstetric 
complications, teratogenicity, and specific drugs. 
Furthermore, all of the reports were based on ob-
servations of traditional AEDs such as phenytoin (PTH), 
Phenobarbital (PB), carbamazepine (CBZ), and valproate 
(VPA). Lamotrigine (LTG) is a second-generation AED 
that is widely used for seizure control in epilepsy as well 
as in other neurologic and psychiatric disorders, and 
was approved by the US Food and Drug Administration 
for use as an AED in 1994.4 The use of LTG increased 
dramatically between 1999 and 2003.5 However, in-
formation on the safety of LTG in human pregnancy is 
still limited. There have been studies on teratogenicity 
of LTG that has a modest teratogenic risk compared to 
other AEDs, with reported rates of major congenital 
malformations from 1.0 to 5.6%.5-10 Several ob-
servational studies have indicated that LTG clearance 
markedly increases during pregnancy, 11-14 with seizures 
worsening in women with epilepsy.11,13 
The purpose of this study was to investigate preg-
nancy outcomes in women with epilepsy using LTG.
Material and Methods
A total of 138 patients with epilepsy who had ante-
natal care and gave births at Yonsei University Health 
System from February 1996 to December 2007 were en-
rolled in this study. Nine patients who were not taking 
antiepileptic drugs (AEDs) were excluded from this 
study. We subdivided the enrolled patients into LTG 
group and other AED group. Of 129 patients, 37 patients 
were exposed to LTG and 92 patients were exposed to 
other AEDs. We retrospectively analyzed their medical 
records to observe pregnancy outcomes including con-
genital malformation, spontaneous abortion, small for 
gestational age (SGA), termination of pregnancy, intra-
uterine fetal death (IUFD), preterm delivery, and ad-
verse maternal outcomes. In women with epilepsy, seiz-
ures were classified by International League Against 
Epilepsy (ILAE).15 Monotherapy was defined as a therapy 
with only 1 type of AED and polytherapy defined as a 
therapy with 2 or more AEDs. SPSS 12.0 for Windows 
(SPSS Inc., Chicago, IL) was used for statistical analy-
sis, and statistical significance was calculated with 
chi-square test and t-test. A P-value <0.05 was con-
sidered statistically significant.
Results
One hundred twenty nine patients were exposed to 
AEDs. Of 129 patients, 37 patients were exposed to LTG 
and 92 patients were exposed to other AEDs. The mean 
of maternal age of LTG group and non-LTG group were 
29.6 years and 30.2 years, respectively. The mean of 
gestational age at delivery of each group were 37.0 
weeks and 37.5 weeks, respectively. Forty eight (37.2%) 
patients underwent cesarean section. Ninety women 
were exposed to monotherapy and 39 were exposed to 
polytherapy. There was no significant difference in ma-
ternal age, 1st trimester medication, and folic acid sup-
plementation between LTG group and non-LTG group 
(Table 1). Twenty four (64.9%) patients were exposed to 
polytherapy in the LTG group and 15 (16.3%) patients in 
the non-LTG group with statistically significant diffe-
rence. The most commonly used AEDs were CBZ (n=52), 
LTG (n=37), VPA (n=34), topramite (TPM) (n=24), phe-
nytoin (PHT) (n=13), and oxcarbazepine (OCZ) (n=6). In 
non-LTG monotherapy, CBZ (n=39), VPA (n=13), PHT 
(n=11), TPM (n=5), OCZ (n=5), phenobarbital (PB) 
(n=2), clonazepam (n=1), and levetiracetam (n=1) were 
used. In polytherapy, LTG+TPM (n=9), LTG+VPA (n=7), 
LTG+VPA+TPM (n=4), LTG+CBZ (n=3), LTG+TPM+VPA 
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Table 1. Patient characteristics (n=129)
Variable
LTG 
(N=37)
Non-LTG 
(N=92)
P-value
Age, years, mean±SD
Primigravida, n (%)
Previous cesarean delivery, n (%)
29.6±3.0
13 (35.1)
 8 (21.6)
30.2±3.3
33 (35.9)
25 (27.2)
 0.349
 1.000
 0.513
Gestational age at delivery, weeks, mean±SD
Cesarean delivery, n (%)
Medication method
37.0±7.0
11 (29.7)
37.5±5.8
37 (40.2)
 0.642
 0.265
<0.001
Monotherapy, n (%) 13 (35.1) 77 (83.7)
Polytherapy, n (%) 24 (64.9) 15 (16.3)
1st trimester medication, n (%)
Folic acid supplementation, n (%)
LTG dose, mg, median (range)
30 (93.8)
35 (94.6)
 200 (50-400)
89 (96.7)
76 (82.6)
 0.722
 0.076
LTG: lamotrigine, CBZ: carbamazepine, VPA: valproate, PTH: phenytoin, PB: phenobarbital, OCZ: oxcarbazepine, TPM: 
topiramate.
Table 2. Congenital malformations according to antiepileptic drug (AED)
Medication Type of malformation
LTG monotherapy None
CBZ monotherapy Spina bifida, Meningomyelocele, TR and PS
VPA monotherapy Anencephaly, Spina bifida
CBZ+VPA polytherapy Spina bifida
Right finger agenesis
Long bone shortening
Total 8/129 (6.2%)
AED: antiepileptic drug, LTG: lamotrigine, CBZ: carbamazepine, VPA: valproate, TR: tricuspid regurgitation, PS: pulmonary 
stenosis, VSD; ventricular septal defect.
+levetiracetam (n=1), VPA+CBZ (n=5), VPA+TPM (n=3), 
VPA+CBZ+TPM (n=1), VPA+CBZ+OCZ (n=1), VPA+CBZ+ 
PTH (n=1), CBZ+TPM (n=2), CBZ+PTH (n=1), TPM+leve-
tiracetam (n=1) were used. 
Out of 129 women with epilepsy, 8 (6.2%) experienced 
congenital malformation. Spina bifida, meningomyelo-
cele, and congenital heart disesase (tricuspid regur-
gitation and pulmonary stenosis) were developed in 
women who were exposed to CBZ only. Spina bifida and 
anencephaly were developed in women who were exposed 
to VPA only. In women exposed to both CBZ and VPA, 
spina bifida, right finger agenesis, and long bone 
shortening were observed (Table 2). There were no mul-
tiple malformations. Of 6 termination cases, 3 cases 
were 1 right hand agenesis and 2 spina bifida.
Generalized tonic-clonic seizure, complex-partial 
seizure, partial seizure were found in 5 (13.5%), 0 (0%), 
and 3 (8.1%) patients respectively in LTG group, and in 
15 (16.3%), 1 (1.1%), 1 (1.1%) patients respectively in 
non- LTG group. These findings were not statistically 
significant. 
There was no significant difference in the incidence of 
spontaneous abortion, SGA, termination of pregnancy, 
IUFD, and preterm delivery and adverse maternal out-
comes between LTG group and non-LTG group. 
However, there was a significant difference in the in-
cidence of congenital malformation (0 vs.8.7%, P= 
0.047). 
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Table 3. Adverse pregnancy outcomes in each antiepileptic drug
Outcome
Monotherapy Polytherapy
LTG 
monotherapy
(N=13)
Non-LTG 
monotherapy
(N=77)
P-value
LTG 
polytherapy
(N=24)
Non-LTG 
polytherapy
(N=15)
P-value
Spontaneous abortion 0 1 (1.3%) 1.000 1 (4.2%) 0 1.000
Intrauterine fetal death 0 1 (1.3%) 1.000 0 0
Termination of pregnancy 1 (7.7%) 1 (1.3%) 0.269 2 (8.3%) 2 (13.3%) 0.631
SGA 0 3 (3.9%) 1.000 2 (8.3%) 0 0.514
Preterm delivery 0 3 (3.9%) 1.000 0 1 (6.7%) 1.000
Placenta previa 0 2 (2.6%) 1.000 0 0
PPROM 2 (15.4%) 2 (2.6%) 0.098 0 1 (6.7%) 0.385
Placental abruption 0 1 (1.3%) 1.000 0 0
Adverse maternal outcomes* 2 (15.4%) 7 (9.1%) 0.613 1 (4.2%) 2 (13.5%) 0.547
Congenital malformation 0 5 (6.5%) 1.000 0 3 (20.0%) 0.049
LTG: lamotrigine, SGA: small for gestational age, PPROM: preterm premature rupture of membranes
*Adverse maternal outcomes: preeclampsia, placenta previa, PPROM, placental abruption
Between LTG monotherapy group and non-LTG mon-
otherapy group, there was no significant difference in 
the incidence of congenital malformation. Congenital 
malformations were developed 5 cases in the non-LTG 
monotherapy group, but this finding was statistically 
insignificant. However, there was statistically sig-
nificant difference in the incidence of congenital mal-
formation between LTG polytherapy group and non-LTG 
polytherapy group. (0 vs. 20.0%, P=0.049) (Table 3). 
One hundred eleven (86.0%) patients received a folic 
acid (4 mg/day) supplement during their first trimester. 
Among these women, 1 (0.8%) experienced spontaneous 
abortion and 1 (0.8%) had a fetal neural tube defect. In 
women without folic acid supplementation, 4 (26.7%) 
experienced spontaneous abortion and 2 (40.0%) experi-
enced IUFD.
Discussion
The incidence of congenital malformation is 2~3 
times higher in women with epilepsy compared to gen-
eral population.15 In our research, the risk rate of con-
genital malformation was 6.2%, which did not deviate 
much from the 6~8% of many other studies. When 
treatment is changed from polytherapy to monotherapy, 
the incidence of congenital malformation decreased 
from 13.5 to 6.2% or 9.6 to 7.6%, and the types of mal-
formation changed to minor ones such as facial clefts, 
dysmorphia to spina bifida, and hypospadias.16 Although 
there are some reports that polytherapy does not neces-
sarily increase the induction of malformation,17 the ma-
jority of studies have reported that polytherapy, espe-
cially with VPA, is related to an increase in the develop-
ment of severe malformation.18 According to the study of 
Dravet, spina bifida occurred in 1% of mothers taking 
VPA, and this result was 20% higher than in the normal 
population. There was a report that polytherapy with 
CBZ can increase spina bifida by 0.5~1%.19  
The newly developed medicine called LTG has been 
studied to determine if it could replace VPA. In the case 
of monotherapy, the researches have been made with the 
61 cases and 647 cases and it was reported that 
0.0~4.4% of severe malformation occurred.6,9 According 
to the study performed between 1992 and 2005 by the 
means of pregnant registration program, 2.8% of severe 
malformation had been observed in 707 cases, implying 
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that LTG is a relatively low-risk drug compared to other 
AEDs.16,20 In this study, congenital malformation did not 
occurred in LTG monotherapy group. 
According to the British pregnant registration re-
search, dosage effects of LTG have been observed. If the 
daily dosage was under 200 mg, 1.6% of severe malfor-
mation was observed whereas for a daily dosage of over 
200 mg, the rate increased to 5.4%. In the turning point 
research by Sabers, the daily average dosage of 385 mg 
was administered to 137 mothers and the risk rate of 
malformation was 2.9%, proving that LTG is relatively 
lower in risk than other AEDs. In this study, women ex-
posed to LTG monotherapy was 13. Except for 1 who ex-
perienced generalized seizure, the daily dose of the drug 
did not exceed 300 mg. Although there were 24 (64.9%) 
women exposed to AED polytherapy in the LTG group, 
no significant differences were observed between the 
LTG group and non-LTG group. 
Obstetric complications were reported to be more 
common in women with epilepsy; include a low birth 
weight, preeclampsia, bleeding, placental abruption, 
and prematurity.21-23 A study on the effect of seizure on 
pregnancy showed that convulsive seizure, especially in 
the form of generalized seizure, can cause hypoxemia 
and have a high death rate for both mothers and unborn 
children.8 Teramo reported that a generalized seizure 
during labor can have a significant impact on fetal heart 
rate.24 It has also been reported that the trauma caused 
by a seizure, especially uterine trauma, can damage the 
myometrium, resulting in the secretion of arachidonic 
acid that can induce uterine contractions or rupture of 
amniotic membranes causing the preterm delivery and 
the placental abruption could be induced.25 According to 
a population-based study of Katz et al, higher rates of 
cesarean deliveries (17.3 vs. 11.55%, P<0.008), and ges-
tational diabetes mellitus (9.1 vs. 5.5%, P<0.02) were 
noted among the epileptic population.26 In this study, in 
non-LTG group, cesarean delivery rate was 40.2%, pre-
term delivery rate was 4.3%. All 4 cases of preterm de-
liveries were in non-LTG group. Moreover, one case of 
placental abruption happened in non-LTG group. The 
incidence of adverse maternal outcomes in the LTG 
monotherapy group was higher than in the non-LTG 
monotherapy group (15.4 vs. 9.1%). These results may 
raise concern about LTG’s safety, but the sample size is 
too small to get wide confidence intervals. 
It is important to emphasize parent counseling re-
garding the potential benefits and hazards of the treat-
ment, including the uncertainty of long term adverse 
effects. Therefore, in the first stage of pregnancy, it is 
important to choose the proper AED to control seizure 
and maintain a minimum level of the drug in the serum. 
Additionally, taking folic acid to decrease the risk of 
congenital malformation, especially to decrease the risk 
of damage to the neural tube, is necessary. As the 
pregnancy progresses to term, it is important to prevent 
seizure by increasing AED level in the serum.27 
Monitoring the development of fetal malformation by 
means of maternal serum alpha-fetoprotein, estimation 
of amniotic fluid volume, and regular ultrasound exam 
should be performed as well.
LTG teratogenicity has proven inconclusive in human 
studies. There is a need to evaluate the possibility of 
minimizing fetal toxicity caused by drugs. To achieve 
this, a prospective study is warranted. 
In conclusion, this study showed that administration 
of LTG polytherapy in pregnant women with epilepsy 
could be more effective in decreasing teratogenicity 
than administration of other combination of AEDs in 
polytherapy. 
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= 국문초록 =
목적: 본 연구는 항간질약을 복용하는 간질 여성에서 lamotrigine 복용 여부에 따른 임신 예후를 조사하고자 하였다. 
연구 방법: 1996년 2월부터 2007년 12월까지 본 병원에서 산전진찰을 시행 받고 분만한 총 138명의 간질 여성에 대해 후향적 
연구를 시행하였다. 9명의 환자는 항간질약을 복용하지 않아 연구에서 제외되었다. Lamotrigine을 복용한 군과 Lamotrigine을 
제외한 항간질약을 복용한 군으로 분류하여 선천성 기형, 자연 유산, 저체중출생아, 임신 종결, 자궁내태아사망, 조기 분만 
그리고 불량한 산모 예후를 비교 분석하였다. 통계 분석은 유의확률이 0.05 미만일 때 유의한 것으로 보았다. 
결과: 항간질약을 복용한 129명의 산모 중 8건 (6.2%)의 선천성 기형이 발생하였다. Carbamazepine 단일제제 사용 군에서 4건, 
valproate 단일제제 사용 군에서 1건, valproate와 carbamazepine 복합제제 사용 군에서 3건의 선천성 기형이 발생하였다. 
Lamotrigine을 복용하지 않은 군에서만 8건 (8.7%)의 선천성 기형이 발생하였고, 이는 통계학적으로 lamotrigine 복용 군과 
유의하게 차이가 있었다 (P=0.047). 특히 복합제제와 단일제제 사용 군으로 나누어 비교하였을 때, 복합제제 사용 군 중, 
lamotrigine을 포함하지 않는 복합제제 사용 군에서 선천성 기형 발생이 유의하게 높게 나타났다 (P=0.049). 자연유산, 저체중
출생아, 임신 종결, 자궁내태아사망, 조기 분만 그리고 불량한 산모의 예후는 두 군간에 차이가 없었다.
결론: 간질이 있는 여성에서 임신 중 Lamotrigine 복용은 복합제제 사용 군에서 다른 약제를 포함한 복합제제를 복용한 경우보
다 선천성기형 발생을 감소시키는 데 더 효과적일 것으로 사료된다. 
중심단어: 간질, 항간질약, 임신 예후, Lamotrigine
